Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Molecular Diagnostics in CML Illustrate Ways to Enhance Well-Established Strategies

January 30th 2015

Although there clearly are a number of worthy candidates for the single most influential event that unequivocally proclaimed the beginning of the modern era of precision cancer medicine, there would surely be many votes for the impact of imatinib on the course of the natural history of chronic myeloid leukemia.

Incyte Medical Officer Elaborates on Ruxolitinib Benefit for Polycythemia Vera

January 29th 2015

For additional insight on the published RESPONSE data and the use of ruxolitnib to treat polycythemia vera, we reached out to Richard Levy, MD, executive vice president and chief drug development and medical officer at Incyte, the company that co-manufactures ruxolitinib with Novartis.

Treating Refractory Idiopathic Thrombocytopenic Purpura

January 27th 2015

Surgery Preperation for Individuals With ITP

January 27th 2015

Splenectomy in Idiopathic Thrombocytopenic Purpura

January 27th 2015

Platelet Transfusions, H. pylori Eradication, and Chemotherapy

January 27th 2015

Thrombopoietin Receptor Agonists for Thrombocytopenia

January 27th 2015

Thrombopoietin Receptor Agonists for ITP

January 27th 2015

Frontline Treatment of Idiopathic Thrombocytopenic Purpura

January 27th 2015

Risk of Thrombosis in Patients With ITP

January 27th 2015

When to Initiate Treatment for ITP

January 27th 2015

Immune Thrombocytopenia Diagnostic Challenges

January 27th 2015

Differential Diagnosis of Immune Thrombocytopenia

January 27th 2015

Dr. Lawrence Mayer on CPX-351 for Acute Myeloid Leukemia

January 23rd 2015

Lawrence Mayer, PhD, president, founder and chief scientific officer of Celator Pharmaceuticals, explains the technology behind CPX-351, a liposomal formulation of cytarabine and daunorubicin. CPX-351 was recently granted Fast Track Designation by the FDA for the treatment of elderly patients with relapsed acute myeloid leukemia (AML).

Dr. Scott Rowley on Allogeneic Stem Cell Transplant

January 21st 2015

Scott Rowley, MD, the Chief of John Theurer Cancer Center's Blood and Marrow Stem Cell Transplantation Division, discusses the challenges of allogeneic stem cell transplant.

Promising Therapies on Horizon for Hodgkin Lymphoma

January 21st 2015

Stem Cell Transplants in Hodgkin Lymphoma

January 21st 2015

Targeting CD30 in Hodgkin Lymphoma

January 21st 2015

Evolving Role of Brentuximab Vedotin in Hodgkin Lymphoma

January 21st 2015

Brentuximab Vedotin in Hodgkin Lymphoma

January 21st 2015